6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
events O
( O
> O
1 O
% O
) O
were O
application O
site O
erythema O
and O
ocular O
erythema O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
ParaPRO O
, O
LLC O
at O
1-855-628-7622 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

NATROBA O
Topical O
Suspension O
was O
studied O
in O
two O
randomized O
, O
active-controlled O
trials O
( O
N=552 O
) O
in O
subjects O
with O
head O
lice O
; O
the O
results O
are O
presented O
in O
Table O
1 O
. O

Table O
1 O
: O
Selected O
Adverse O
Events O
Occurring O
in O
at O
least O
1 O
% O
of O
Subjects O
Signs O
Spinosad O
( O
N=552 O
) O
Permethrin O
1 O
% O
( O
N=457 O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
17 O
( O
3 O
% O
) O
31 O
( O
7 O
% O
) O
Ocular B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
12 O
( O
2 O
% O
) O
15 O
( O
3 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
5 O
( O
1 O
% O
) O
7 O
( O
2 O
% O
) O
Other O
less O
common O
reactions O
( O
less O
than O
1 O
% O
but O
more O
than O
0.1 O
% O
) O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
dryness I-OSE_Labeled_AE
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
.Systemic O
safety O
was O
not O
assessed O
in O
pediatric O
subjects O
under O
6 O
months O
of O
age O
as O
laboratory O
parameters O
were O
not O
monitored O
in O
these O
controlled O
studies O
. O

